Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab

Published:2022-01-01 Issue:1 Volume:61 Page:75-79
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sakaguchi Hiroyuki¹,Tanimoto Azusa¹,Sato Shigeki¹,Yanagimura Naohiro¹,Suzuki Chiaki¹,Takumi Yohei¹,Nishiyama Akihiro¹,Yamashita Kaname¹,Takeuchi Shinji¹,Ohtsubo Koshiro¹,Yano Seiji²

Affiliation:

1. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan

2. WPI-Nano Life Science Institute (WPI-Nano LSI), Kanazawa University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/1/61_7452-21/_pdf

Reference11 articles.

1. 1. Karuppiah SV, Buchan KG. Primary malignant melanoma: a rare cause of mediastinal mass. Jpn J Thorac Cardiovasc Surg 54: 396-398, 2006.

2. 2. Park SY, Kim MY, Chae EJ. Primary malignant melanoma of the mediastinum: radiologic and pathologic correlation in two case. Korean J Radiol 13: 823-826, 2012.

3. 3. Li Z, Jia H, Zhang B, Zhang Y, Li H, Song P. The clinical features, treatment, and prognosis of primary mediastinal malignant melanoma: a case report. Medicine (Baltimore) 96: e6436, 2017.

4. 4. Youn HC. A primary malignant melanoma of the mediastinum with gross surgical view. J Thorac Dis 8: E133-E136, 2016.

5. 5. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377: 1345-1356, 2017.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP